DarioHealth Cuts Pharmaceutical Business, Eyes Multi-Condition Growth
Event summary
- Q2 2026 revenue fell to $5.2M, down from $5.4M in Q2 2025 due to discontinuation of pharmaceutical business.
- Gross margin improved to 62%, up from 55% in Q2 2025, with non-GAAP B2B2C gross margins at ~80% for the 10th consecutive quarter.
- Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter.
- Signed new Fortune 50 client representing over 100,000 eligible employees and a major health insurer in Arizona through Amwell partnership.
- Raised $22.8M in July 2026 via registered direct financing, bringing pro forma cash to $36.8M.
The big picture
DarioHealth is pivoting away from one-time pharmaceutical services to focus on its AI-powered multi-condition platform, aiming to capture more of the healthcare value chain through partnerships and provider-backed care. The company's improved gross margins and reduced operating losses signal progress in operational efficiency, but revenue growth will depend on the success of its new strategic initiatives.
What we're watching
- Revenue Diversification
- Whether DarioHealth can sustain growth through its multi-condition strategy and new partnerships after exiting the pharmaceutical business.
- Operational Efficiency
- The pace at which AI-driven capabilities like DarioIQ™ will increase recurring revenue from existing customers.
- Market Expansion
- How successful the provider-backed care strategy will be in capturing a larger share of the healthcare value chain.